Product information and disease descriptionPlace of product in therapyDisease descriptionEpidemiology
Prevalence of Moderate-to-severe plaque psoriasis
18 evidence topics · 12 sources
Prevalence in U.S. adults: National Health Interview Survey 2023
Prevalence in U.S. adults by sex, race and ethnicity, and body mass index, 2023
Prevalence in U.S. adults 20 years or older
“Psoriasis prevalence among US adults 20 years or older was 3.0% (95% CI, 2.6%-3.4%).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Based on the 2020 census data, psoriasis affects approximately 7.55 million US adults aged 20 years or older.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Prevalence in U.S. adults by race and ethnicity and over time, NHANES
“Overall, White individuals reported the highest prevalence of psoriasis at 3.6% (95% CI, 2.9%-4.2%). The lowest psoriasis prevalence was found in Black individuals, with a prevalence of 1.5% (95% CI, 1.0%-2.0%).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The prevalence of psoriasis among those aged 20 to 59 years within the 2011-2014 NHANES data was 2.9% (95% CI, 2.5%-3.4%). This most recent prevalence estimate was not statistically different from prevalence estimates from prior years of 2.9% (95% CI, 2.3%-3.5%) during the 2009-2010 NHANES cycle and 3.2% (95% CI, 2.2%-4.5%) from the 2003-2004 NHANES cycle (P = .84).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Prevalence trend in U.S. adults: NHANES and NHIS, 2003 to 2024
“Data from the 2003-2006 and 2009-2014 National Health and Nutrition Examination Survey and the 2023-2024 National Health Interview Survey were analyzed.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“The total sample included 53,225 participants.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“No temporal trends in prevalence were found in any sociodemographic subgroup.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Diagnosed and undiagnosed psoriasis in U.S. adults
“The prevalence of diagnosed psoriasis was 3.15% (95% CI 2.18, 4.53), corresponding to 5 million adults. The prevalence of undiagnosed active psoriasis by conservative estimate was 0.4% (95% CI 0.19, 0.82) corresponding to approximately 600,000 US adults.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Moderate-to-severe fraction: three or more palms of body surface area
“In this study, we found that 21.5% of participants reported having moderate to severe psoriasis (≥3 palms of body surface area involvement).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The majority of patients with psoriasis reported having little or no psoriasis at the time of the survey.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Reported severity: no or little, mild, and moderate or severe disease
“Psoriasis severity was generally mild: 54.5% (95% CI=44.8, 63.9) reported no or little disease; 27.3% (95% CI=21.1, 34.6) reported mild disease; and 18.2% (95% CI=12.4, 25.9) reported moderate or severe disease.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Moderate-to-severe fraction and number affected, ages 20 to 59
| Body surface area category | Proportion of psoriasis patients |
|---|---|
| Little or no psoriasis | “51.59%”View highlighted excerpt for this quote |
| 1% to 2% | “31.68%”View highlighted excerpt for this quote |
| 3% to 10% | “11.38%”View highlighted excerpt for this quote |
| More than 10% | “5.25%”View highlighted excerpt for this quote |
“83.37% of psoriasis patients with a history of physician diagnosis had mild psoriasis (little/no to 1–2% BSA) while 16.63% had moderate to severe disease (3% or greater BSA).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Furthermore, we estimate that 1.4 million patients age 20–59 have moderate to severe disease and that 2.1 million consider psoriasis to be a large problem in daily life.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Psoriasis prevalence and severity distribution in the adult population
“The median prevalence of psoriasis in the adult population using the Bayesian estimate was 3.0% (95% credibility interval, 2.7–3.3%), compared with the estimated mean prevalence of 3.4% (95% confidence interval, 2.2–4.9%). By EE, the estimated cumulative distribution of disease severity assessed by BSA suggests that approximately 50% of patients have a BSA of < 3% and 78% of patients have a BSA of < 10%, with only 2% having a BSA of > 50%.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Based on EE, approximately 22% of the adult population with psoriasis has 10% or more of BSA involved.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Insured U.S. population with moderate-to-severe psoriasis and untreated share
“There were an estimated 1.7 million insured US patients with moderate to severe psoriasis. Of these, 1 million (59%) were not treated for their condition in the preceding year.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Assigning disease severity by treatment types, excluding patients with mild disease (4,065,721) and those prescribed treatment for a related inflammatory comorbidity (191,753), resulted in an estimated 1,700,266 insured patients with moderate to severe psoriasis in the 5-year analysis window (Fig. 4). Of these, 546,814 (32.2%) were diagnosed but not treated.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Treatment types received by insured U.S. patients with moderate-to-severe psoriasis
“Furthermore, of the patients treated (lapsed + currently treated) in the prior year, 156,409 (22.5%), 222,657 (32.0%), 22,911 (3.3%), and 293,511 (42.2%) received a biologic, traditional oral systemic, phototherapy, or a topical treatment, respectively (Fig. 4).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“In conclusion, this large health-plan-claims-based study showed that 40.9% of 1.7 million eligible US patients were receiving therapy for moderate to severe psoriasis in the 12 months up to September 2012.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Claims-based prevalence and severity distribution
“Based on several psoriasis identification algorithms, the claims-based prevalence for psoriasis in the United States ranged from 0.51% to 1.23%.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Using this method, 70.9% of patients had mild disease and 27.3% had moderate to severe disease (Table 4).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Therapies received in the claims analysis
“Most patients had at least one claim for psoriasis therapy (83.5%), and 16.5% received no therapy. Topical therapies were used by 76.6% (N=3,551), the majority of whom received topical corticosteroids (97.9%). Phototherapy was used by 7% (N=324). Oral systemic medications were used by 14.3% (N=664), the majority of whom received methotrexate (85.7%).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Prevalence, severity at its worst, and undertreatment
“The prevalence of psoriasis/PsA ranged from 1.4% to 3.3%; 79% had psoriasis alone and 21% had PsA. When rating disease severity at its worst, 27% (psoriasis) and 53% (PsA ± psoriasis) of patients rated it as severe.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Of psoriasis patients, 45% had not seen a physician in a year; >80% of psoriasis patients with ≥ 4 palms body surface area and 59% of PsA patients were receiving no treatment or topical treatment only.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Regional prevalence, including high income North America
“The prevalence of psoriasis varied from 0.14% (95% uncertainty interval 0.05% to 0.40%) in east Asia to 1.99% (0.64% to 6.60%) in Australasia.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Other regions with an occurrence of the disease above 1% were western Europe (1.92%, 1.07% to 3.46%), central Europe (1.83%, 0.62% to 5.32%), high income North America (1.50%, 0.63% to 3.60%)” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Global prevalent cases, Global Burden of Disease Study 2021
“In 2021, the global prevalence number of people with psoriasis reached 42.98 million cases (95% CI: 41.65~44.31 million), representing an increase of approximately 86.4% compared to the number of cases in 1990.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote